J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements

Johnson & Johnson has suspended enrollment in its NEVO II trial comparing its next-generation Nevo stent to Abbott's market-leading Xience V stent, citing needed improvements to the balloon catheter component of the system, the firm announced Oct. 19.